This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Comparing Neurocrine Biosciences pediatric study results of Crinecerfont in Children and Adolescents with Spruce Biosciences Tildacerfont CAHptain-205 study and dose finding presentation at the Pediatric Endocrine Society (PES) 2024

Ticker(s): SPRB, NBIX

Who's the expert?

Endocrinologist who manages patients with CAH

Interview Questions
Q1.

How did the crinecerfont pediatric study patient population baselines compare with tildacerfont's CAHptain study? 

Added By: gpcphoenix
Q2.

What is the range in pediatric congenital adrenal hyperplasia (CAH) patient disease characteristics compared to adult population? 

Added By: gpcphoenix
Q3.

Can crincerfont or tildacerfont pediatric intervention theoretically stop disease progression as patients reach adulthood? 

Added By: gpcphoenix
Q4.

I'd like to add more questions prior to hosting the call based upon the data presented at the Pediatric Endocrine Society meeting this week, and company conversations next week and at investor conferences mid-month. 

Added By: gpcphoenix

Are You Interested In These Questions?

Slingshot Insights Explained
23Hours Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.